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Abstract
Purpose To validate the Dutch version of the EORTC
QLQ-CR29 quality of life questionnaire for colorectal
cancer.
Methods We translated and pilot-tested the original
questionnaire in the Netherlands, following EORTC
guidelines. We assessed factor structure, reliability and
construct validity in different samples of patients from four
hospitals.
Results Of 296 patients, 236 (80 %) returned the ques-
tionnaire, and 27 out of 48 patients returned the retest
questionnaire. In addition to the original three scales, we
found a reliable bowel functioning scale (a = 0.80),
reducing the number of individual items by five. Two of
the other scales had sufficient to good reliability (urinary
frequency, a = 0.71, original a = 0.75, body image
a = 0.80, original a = 0.84), the third, blood and mucus in
stool, only moderate (a = 0.56, original a = 0.69). Item
functioning was sufficient to excellent for all but two items
(urinary incontinence and dysuria). Construct validity was
similar to that in earlier studies.
Conclusion We found a very satisfactory scale for bowel
problems, in patients both with and without stoma. The
body image and urinary incontinence scales were reliable,
and construct validity was sufficient. We suggest the
questionnaire to be adapted to decrease the number of
individual items, improve the scales, and therefore increase
reliability of the entire questionnaire.
Keywords Health-related quality of life  Colorectal
cancer  QLQ-CR29  Validation
Introduction
Colorectal cancer is a prevalent cancer, and both the dis-
ease and its treatment strongly impact quality of life (QoL).
To allow for the evaluation of new treatments, the Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) developed the colorectal QoL module QLQ-
CR38 [1] as an adjunct to the generic EORTC QLQ-C30.
Later, this was revised to the shorter QLQ-CR29 [2] and
validated in an international study [3]. The resulting QLQ-
CR29 consisted of four scales and 19 individual items.
Later validation studies were reported for the Polish [4] and
Spanish [5] versions. Validation of the Danish QLQ-CR38
[6] suggested the QLQ-CR29 to be more valid than the
QLQ-CR38. In the Spanish QLQ-CR29, the blood and
mucus scale was not confirmed; in the Polish only the body
image scale was reliable, and the urinary incontinence
scale approached acceptable reliability. Construct validity
was limited for the Polish version and showed ambiguous
results for the Spanish. In both cases, the authors never-
theless concluded the questionnaire to be reliable and valid.
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These equivocal results led us to assess the reliability and
validity of the Dutch version and to assess whether addi-




The QLQ-CR29 had been translated into Flemish/Dutch by
the EORTC Quality of Life Group, following their Trans-
lation Procedure Manual Instructions [7]. Differences in
the Dutch language exist between Belgium and the
Netherlands, and pilot testing was undertaken to reword
some items for a Dutch population, in 29 patients with
colorectal cancer from the Leiden University Medical
Center (LUMC). Suggested changes were discussed with
experts of the EORTC, resulting in a final Dutch
translation.
Consecutive patients were recruited from two academic
and two peripheral hospitals in the western region of the
Netherlands [LUMC—Departments of Surgery and
Radiotherapy, Alrijne Hospital Leiden (former locations
Diaconessen Hospital and Rijnland Hospital)], and Eras-
mus Medical Center Rotterdam, between May 2011 and
December 2012. In three departments (Diaconessen
Hospital, LUMC—Surgery, and ErasmusMC), research
nurses handed the questionnaire to the patients (n = 123,
response rate 79 %) at the time of their follow-up visit, and
in one hospital (Rijnland), the questionnaire was sent to
patients (n = 80, response rate 83 %) who had undergone
treatment for colorectal cancer between May and Decem-
ber 2011. In one department (LUMC—Radiotherapy), the
questionnaire was sent to patients (n = 93, response
rate = 78 %) who participated in other studies [8, 9]. Of
the 296 patients receiving a questionnaire, 244 returned it,
and we included 236 completed questionnaires (response
80 %). Time between surgery and filling out the ques-
tionnaire ranged from 5 months to 12 years. No informa-
tion is available on the non-responders, unfortunately, but
given the nature of the task, filling out a short question-
naire, we do not expect major non-response bias.
For convergent validity, participants were additionally
asked to fill out the EORTC QLQ-C30. For test–retest
reliability, we approached patients who had indicated their
willingness in the first questionnaire. The questionnaire
was sent to every fifth participant within 2 weeks of
returning the first questionnaire. Twenty-seven patients
(out of 48 invited, 56 %) filled in the questionnaire twice,
on average 19 days after the first (range 4–46 days).
Patient characteristics are presented in Table 1.
Statistical analysis
We assessed item performance, by proportion of floor and
ceiling effects, and by test–retest reliability (intraclass
correlation coefficients, ICCs). Since the QLQ-CR29 was
shown to consist only of few and mostly two-item scales,
we carried out a principal component analysis to detect
potential additional subscales, based on eigenvalues ([1.0).
Items 49–54 on bowel problems (patients without a stoma)
and stoma problems (patients with a stoma), respectively,
were used as if the same items for patients without and with
a stoma. We used varimax rotation to facilitate interpre-
tation [10]. We assessed scale reliability using Cronbach’s
a, for both the newly found scales and the original four
scales. Subscales were constructed on the basis of the
principal component analysis by adding the unweighted
scores of the variables that loaded on a factor and nor-
malizing to 0–100. Finally, we assessed construct validity
as done in the earlier studies [4, 5], using correlations with
the QLQ-CR30 (scores below 0.40 indicating no undue
overlap between the constructs of the two questionnaires),
and known-groups comparisons comparing older
(C66 years) and younger (B65 years), patients with and
without a stoma, and patients treated with curative and
palliative intent using Mann–Whitney U tests.
Results
Characteristics of items
Table 2 presents the item characteristics and the subscales
detected. ICCs were low for urinary incontinence and
dysuria. The percentage respondents at floor was rather
high ([50 %) in the blood and mucus in stool scale and for
19 individual items.
Factor analysis and reliability
Factor analysis revealed seven factors, of which the orig-
inal urinary frequency scale (Cronbach’s a = 0.71) and
body image (a = 0.80) scales were reproduced (alpha in
the original study [3] of 0.71 and 0.84, respectively). The
original two-item stool frequency scale (items 52 and 53)
had a lower a (0.68, originally 0.70 [3]) than when included
in a larger factor, with all bowel and stoma problems
included (items 49–54: a = 0.80). This latter scale also
showed good reliability for patients with (a = 0.80) and
without (a = 0.84) a stoma. The blood or mucus in stool
scale was reproduced in the factor analysis but had a low a
of 0.56 (originally 0.69 [3]). All remaining factors did not
form clearly interpretable scales, and reliabilities were all
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below 0.70. We thus present construct validation for the
original scales and items, as well as the new bowel/stoma
problems scale.
Construct validity
Correlations between the subscales and the QLQ-C30
subscales were below 0.40, except for body image, which
correlated moderately (r = 0.48) with social functioning.
Younger compared to older patients had significantly
worse sexual functioning (Table 3) and had fewer prob-
lems with urinary frequency and incontinence and with a
dry mouth. Patients without a stoma had a higher body
image and less urinary incontinence. Patients treated with
curative intent indicated more problems with blood and
mucus in stool, defaecation problems, buttock pain, and
stool frequency and fewer problems with hair loss and
trouble with taste than patients treated with palliative
intent.
Discussion
This study largely replicates the findings of the original
study [3] and the Spanish validation [5]. As in the original
study, the body image and urinary frequency scales were
reliable, while the blood and mucus scale was only mod-
erately reliable. An important result is that we found a
reliable scale incorporating the items about bowel prob-
lems or stoma problems. Neither the Spanish nor the Polish
study performed an exploratory factor analysis and only
reported the results for the scales defined in the original
paper [3]. Since the original stool frequency scale was
incorporated in this new scale, the questionnaire still con-
sists of four scales, but with 14 additional single items
instead of 19. For reasons of reliability and multiple test-
ing, it is recommended to have as few single items as
possible, so this is an improvement.
Remarkable was the better item performance in our
study compared to the Spanish validation, where ceiling
effects were present in over 50 % of the scores in four
domains (body image, anxiety, weight, and impotence).
The patients in our sample scored markedly lower than
those in the Spanish study, likely reflecting in part cultural
values about body image and sexuality. Dysuria had similar
high floor effects in the Spanish [5] and Danish [6] studies.
We recommend additional assessment of the items urinary
incontinence and dysuria, which showed poor reliability
and item performance.
Reliabilities of the items in the original study were
higher than ours (ICCs[ 0.55). The other studies did not
report test–retest reliability.
Construct validity was sufficient, as shown by only
limited overlap between the QLQ-CR29 and QLQ-C30
(similar to the original study [3], apart from the correlation
only we found between body image and social function-
ing). We also found differences in scores between groups
that were well interpretable. We found fewer differences
between patients with and without a stoma than the original
study [3] (which also saw differences for the urinary






Mean age, years ± SD (range) 65 ± 11.3 (24–90) 64 ± 14.1 (24–83)
B65 years 114 (48 %) 13 (48 %)
Male 143 (61 %) 20 (74 %)
Marital statusa
Single 34 (15 %) 8 (30 %)
Married 172 (75 %) 18 (67 %)
Widow(er) 24 (10 %) 1 (4 %)
Educational levela
Low 74 (32 %) 7 (28 %)
Intermediate 91 (40 %) 11 (44 %)
High 64 (28 %) 7 (28 %)
Stoma, yesb 68 (29 %) 12 (44 %)
Curative treatment 196 (83 %) 23 (82 %)
a Does not count up to 236 due to missing data
b At the time of filling in the questionnaire
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frequency scale and the faecal incontinence, sore skin, and
embarrassment items). Further, patients receiving palliative
treatment in that study reported more problems with hair
loss, anxiety, faecal incontinence, and dyspareunia,
whereas in our study they reported less blood and mucus in
stool and buttock pain, and lower stool frequency.
In conclusion, we were able to replicate earlier findings,
but could also reduce the number of single items and thus
Table 2 Quality of life scores according the EORTC QLQ-CR29, structure and reliability
Scaling/single-item name n Item No. Mean SD a % floorc % ceilingc Range ICCsa
All patients 236
Urinary frequency 31, 32 32.2 24.0 0.71 22.2 1.7 0–100 0.33, 0.43
Blood and mucus in stool 38, 39 7.9 15.9 0.56 74.5 0 0–83.3 0.90, 0.72
Body image 45–47 18.5 21.7 0.80 36.0 1.3 0–100 0.76, 0.44, 0.41
Defaecation/stoma problems 49–54 21.4 19.1 0.84 9.6 0 0–88.9 see below
Urinary incontinence 33 7.6 18.2 82.3 0.9 0–100 0.20
Dysuria 34 4.1 13.7 90.2 0.4 0–100 0.36
Abdominal pain 35 11.7 22.2 73.6 2.1 0–100 0.79
Buttock pain 36 14.2 24.8 70.1 2.6 0–100 0.74
Bloated feeling 37 16.0 22.7 61.1 1.3 0–100 0.55
Dry mouth 40 18.6 25.7 58.9 2.5 0–100 0.93
Hair loss 41 8.3 20.9 83.3 2.1 0–100 0.82
Trouble with taste 42 12.3 24.9 75.7 3.4 0–100 0.75
Anxiety 43 33.8 26.4 26.3 4.2 0–100 0.54
Weight 44 20.6 26.6 55.3 3.0 0–100 0.71
Patients without stoma 168
(2) Flatulence 49 34.6 27.4 27.1 3.8 0–100 0.64b
(2) Faecal incontinence 50 12.1 23.2 73.8 2.5 0–100 0.75b
(2) Sore skin around anus 51 14.7 26.8 70.8 5.0 0–100 0.82b
(2) Stool frequency 52, 53 24.1 22.6 0.68 30.0 0.6 0–100 0.81b, 0.27b
(2) Embarrassed by defaecation pattern 54 21.1 30.0 60.2 5.0 0–100 0.65b
Defaecation problems 49–54 21.8 19.6 0.84 9.9 0 0–88.9
Patients with stoma 68
(2) Flatulence 49s 30.3 23.0 28.4 0 0–66.7 See no stomab
(2) Faecal incontinence/leakage 50s 20.2 26.7 57.6 1.5 0–100
(2) Sore skin around stoma 51s 21.9 30.5 58.2 6.0 0–100
(2) Stool frequency/bags change 52s, 53s 14.4 20.4 0.72 56.1 0 0–83.3
(2) Embarrassed by stoma 54s 20.9 27.1 55.2 3.0 0–100
(2) Stoma care problems 55s 8.6 19.7 81.8 0 0–66.7
Stoma problems 49–54s 20.4 17.9 0.80 9.0 0 0–77.8
Male 143
(1) Sexual functioning 26 30.6 25.4 31.1 2.2 0–100 0.85b
(2) Impotence 27 41.7 41.7 42.3 26.0 0–100 0.78b
Female 93
(1) Sexual functioning 28 16.1 22.8 61.2 1.2 0–100 See malesb
(2) Dyspareunia 29 14.5 28.5 74.5 5.5 0–100
a If two or more correlations are presented, these are in order of the items in column 3
b ICCs are for patients with and without stoma (defaecation) and males and females (sex) combined
c Percentages scoring lowest (floor) and highest (ceiling) category
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improve on the QLQ-CR29 as published so far. We rec-
ommend that the remaining individual items be revised to
improve their performance, and that following that, more
psychometric research be carried out to reduce the number
of individual items.
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Table 3 Known-groups comparisons (age, stoma, treatment intent)
CR29 Age Stoma Treatment curative intent
B65 C66 p No Yes p Yes No p
Urinary frequency 26.0 (21.4) 38.1 (25.0) .00*** 32.1 (24.6) 32.3 (22.6) .89 32.5 (24.8) 30.8 (20.2) .85
Blood and mucus in stool 9.2 (17.8) 6.6 (13.9) .33 9.3 (17.6) 4.3(9.7) .09 9.2 (17.0) 1.3 (4.4) .00***
Body image 20.4 (23.2) 16.7 (20.1) .24 14.0 (18.6) 29.4 (24.6) .00*** 18.6 (22.3) 17.6 (18.4) .70
Defaecation/stoma problems 19.9 (18.7) 22.8 (19.5) .19 21.8 (19.6) 20.4 (17.9) .79 22.4 (19.0) 16.9 (19.4) .05*
Urinary incontinence 4.7 (13.2) 10.5 (21.7) .03* 5.8 (15.6) 12.1 (23.1) .02* 7.6 (18.0) 7.7 (19.4) .77
Dysuria 5.3 (15.7) 3.3 (11.7) .22 3.8 (13.4) 5.1 (14.6) .46 4.6 (14.2) 1.7 (10.5) .10
Abdominal pain 11.7 (23.0) 11.7 (21.4) .82 12.7 (23.3) 9.0 (18.9) .32 11.8 (22.3) 10.8 (21.9) .80
Buttock pain 14.2 (25.9) 14.3 (23.9) .70 11.3 (22.7) 21.7 (28.3) .00*** 15.7 (25.4) 7.5 (20.7) .03*
Bloated feeling 18.4 (24.7) 13.9 (20.5) .18 17.2 (22.8) 13.4 (22.5) .16 16.7 (23.3) 13.3 (19.7) .50
Dry mouth 11.7 (19.8) 25.1 (28.8) .00*** 18.3 (25.7) 19.6 (25.9) .68 17.7 (24.4) 23.3 (31.3) .41
Hair loss 90.9 (22.4) 92.5 (19.5) .67 8.8 (21.7) 7.1 (19.0) .66 5.5 (15.1) 23.9 (35.0) .00**
Trouble with taste 12.7 (24.5) 12.0 (25.4) .66 12.0 (25.1) 13.2 (24.5) .47 10.9 (24.5) 19.2 (26.0) .01*
Anxiety 33.6 (27.9) 33.9 (25.0) .79 35.5 (26.6) 29.4 (25.5) .10 32.1 (24.9) 41.7 (31.8) .09
Weight 18.1 (27.0) 22.9 (26.2) .08 18.6 (26.0) 25.5 (27.7) .04* 21.8 (26.8) 14.5 (25.1) .07
Without stoma
Flatulence 32.1 (27.3) 37.1 (27.6) .27 36.1 (26.5) 7.6 (30.9) .08
Faecal incontinence 12.1 (23.3) 12.1 (23.3) 1.0 13.2 (23.3) 6.9 (22.5) .05*
Sore skin around anus 16.1 (27.9) 13.3 (25.8) .45 14.9 (27.1) 13.8 (26.0) .85
Stool frequency 23.9 (23.3) 24.3 (22.0) .82 25.7 (23.1) 16.7 (18.4) .05*
Embarrassed by defaecation
pattern
16.5 (26.4) 25.8 (32.7) .08 22.5 (30.1) 14.9 (29.0) .15
With stoma
Flatulence 28.7 (21.3) 31.6 (24.4) .65 29.8 (23.5) 33.3 (12.1) .62
Faecal incontinence/leakage 16.7 (24.8) 22.8 (28.1) .36 21.8 (27.4) 12.1 (22.5) .26
Sore skin around stoma 23.0 (32.2) 21.1 (29.4) .91 23.2 (31.7) 15.1 (22.9) 54
Stool frequency/bags change 11.5 (20.9) 16.7 (20.0) .12 13.9 (20.2) 1637 (22.3) .59
Embarrassed by stoma 14.9 (22.9) 25.4 (29.4) .15 20.8 (26.6) 21.2 (30.8) .95
Stoma care problems 6.0 (15.9) 10.5 (22.1) .44 9.1 (20.7) 6.1 (13.5) .90
Male
Sexual functioninga 37.6 (26.7) 23.1 (22.0) .00*** 31.1 (25.4) 29.4 (25.7) .68 31.9 (25.4) 22.8 (25.0) .14
Impotence 37.3 (42.1) 47.0 (41.1) .21 33.3 (38.6) 61.3 (42.7) .00*** 40.9 (41.0) 47.1 (47.2) .71
Female
(1) Sexual functioninga 26.7 (26.4) 6.7 (13.5) .00*** 18.8 (24.6) 8.7 (15.0) .10 16.4 (23.3) 14.6 (21.0) .86
(2) Dyspareunia 21.0 (32.2 8.3 (23.4) .06 9.2 (21.3) 28.9 (39.6) .07 15.9 (30.9) 9.1 (15.6) .89
Higher scores indicate higher levels of symptoms or less functioning
* p B .05; ** p B .01; *** p B .001 (Mann–Whitney U test)
a In this area higher scores represent better functioning
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